Refile: BUZZ-Dermapharm Holding slips after BaFin's audit
REFILE-BUZZ-Dermapharm Holding slips after BaFin's audit Removes extraneous word from headline.
** Germany’s Dermapharm Holding DMPG.DE slip 3% after BaFin issued an audit, flagging potential discrepancies in the balance sheet
** According to the Federal Supervisory Authority BaFin, a €63.2 million receivable, including related interest income, may have been incorrectly presented in the balance sheet
** The regulator also says there are indications that transactions with a related party have not been adequately explained
** BaFin said it would publish the outcome of the review regardless of whether it finds any accounting errors
** When asked, the company did not immediately provide Reuters with a comment
(Reporting by Orest Dovhan)
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit